tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2019-9-3s1-23-25tumors-660Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISСТЕРЕОТАКСИЧЕСКАЯ ЛУЧЕВАЯ ТЕРАПИЯ В ФОКУСЕ СИСТЕМНЫХ ИММУНОЛОГИЧЕСКИХ ЭФФЕКТОВБалдуеваИ. А.

Санкт-Петербург

ЗозуляА. Ю.

Санкт-Петербург

antonzozulya@yandex.ruНовиковС. Н.

Санкт-Петербург

ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииRussian Federation20192611201993s12325Copyright © Балдуева И.А., Зозуля А.Ю., Новиков С.Н., 20192019Балдуева И.А., Зозуля А.Ю., Новиков С.Н.Балдуева И.А., Зозуля А.Ю., Новиков С.Н.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/660

Системный эффект лучевой терапии, характеризующийся регрессом отдаленных очагов после локального облучения, носит название абскопального эффекта. Существует мнение, что системное действие радиотерапии опосредовано иммунологическими феноменами. В связи с последними успехами иммунотерапии растет интерес к совместному применению с лучевой терапией с целью увеличения частоты системных эффектов. Однако частота возникновения абскопальных эффектов после применения стандартно- го лучевого лечения остается невысокой. В этом аспекте, стереотаксическая лучевая терапия (СТЛТ), учитывая свои выраженные иммуногенные свойства, высокие показатели локального контроля, низкую токсичность и короткие сроки лечения, по‑видимому, является наиболее подходящим партнером для иммунотерапии у больных с метастатическими формами злокачественных новообразований. В статье рассматриваются механизмы радиоиндуцированного иммунного ответа, иммунологические феномены СТЛТ, различные подходы при комбинированном применении радиотерапии и иммунотерапии, результаты клинических исследований.

стереотаксическая лучевая терапия (СТЛТ)радиотерапияиммунотерапияабскопальный эффектReferencesSridharan V., Schoenfeld J.D. Immune effects of targeted radiation therapy for cancer // Discov Med. 2015 Mar;19 (104):219–28.Sridharan V., Schoenfeld J.D. Immune effects of targeted radiation therapy for cancer // Discov Med. 2015 Mar;19 (104):219–28.Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 2018; 18 (5): 313–322. https://doi.org/10.1038/nrc.2018.6.Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 2018; 18 (5): 313–322. https://doi.org/10.1038/nrc.2018.6.Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol 1953;26:234–241. https://doi.org/10.1259/0007‑1285‑26‑305‑234.Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol 1953;26:234–241. https://doi.org/10.1259/0007‑1285‑26‑305‑234.Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 2007;13:7271–7279. https://doi.org/10.1158/1078–0432.CCR-07–1595.Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 2007;13:7271–7279. https://doi.org/10.1158/1078–0432.CCR-07–1595.Marconi R, Strolin S, Bossi G, Strigari L. A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? PLoS ONE 2017;12 (2): 1–16. https://doi.org/10.1371/journal.pone.0171559.Marconi R, Strolin S, Bossi G, Strigari L. A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? PLoS ONE 2017;12 (2): 1–16. https://doi.org/10.1371/journal.pone.0171559.Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009;114: 589–595. https://doi.org/10.1182/blood-2009‑02‑206870.Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009;114: 589–595. https://doi.org/10.1182/blood-2009‑02‑206870.Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM. IFN-gamma mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol 2013; 182:2345–2354. https://doi.org/10.1016/j.ajpath.2013.02.041Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM. IFN-gamma mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol 2013; 182:2345–2354. https://doi.org/10.1016/j.ajpath.2013.02.041Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti SC, Dustin ML, Demaria S. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008;181:3099–3107. https://doi.org/10.4049/jimmunol.181.5.3099Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti SC, Dustin ML, Demaria S. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008;181:3099–3107. https://doi.org/10.4049/jimmunol.181.5.3099Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 1996;56:5150–5155.Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 1996;56:5150–5155.Xing D, Siva S, Hanna GG. The abscopal effect of stereotactic radiotherapy and immunotherapy: fool»s gold or el dorado? Clin Oncol (R Coll Radiol). 2019; 31 (7): 432–443. https://doi.org/10.1016/j.clon.2019.04.006.Xing D, Siva S, Hanna GG. The abscopal effect of stereotactic radiotherapy and immunotherapy: fool»s gold or el dorado? Clin Oncol (R Coll Radiol). 2019; 31 (7): 432–443. https://doi.org/10.1016/j.clon.2019.04.006.Trujillo JA, Sweis RF, Bao R, Luke J J. T cell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection. Cancer Immunol Res 2018;6:990–1000. https://doi.org/10.1158/2326–6066.CIR-18–0277.Trujillo JA, Sweis RF, Bao R, Luke J J. T cell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection. Cancer Immunol Res 2018;6:990–1000. https://doi.org/10.1158/2326–6066.CIR-18–0277.Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925–931. https://doi.org/10.1056/NEJMoa1112824.Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925–931. https://doi.org/10.1056/NEJMoa1112824.Okwan-Duodu D, Pollack BP, Lawson D, Khan MK. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol 2015;38:119–125. https://doi.org/10.1097/COC.0b013e3182940dc3.Okwan-Duodu D, Pollack BP, Lawson D, Khan MK. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol 2015;38:119–125. https://doi.org/10.1097/COC.0b013e3182940dc3.Van deWalle M, Demol J, Staelens L, Rottey S. Abscopal effect in metastatic renal cell carcinoma. Acta Clin Belg 2017;72:245–249. https://doi.org/10.1080/17843286.2016.1201614.Van deWalle M, Demol J, Staelens L, Rottey S. Abscopal effect in metastatic renal cell carcinoma. Acta Clin Belg 2017;72:245–249. https://doi.org/10.1080/17843286.2016.1201614.Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013;1: 365–372. https://doi.org/10.1158/2326–6066.CIR-13–0115.Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013;1: 365–372. https://doi.org/10.1158/2326–6066.CIR-13–0115.Theelen W, Peulen H, Lalezari F, de Vries J, De Langen J, Aerts J. Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: the PEMBRO-RT study. J Clin Oncol 2018;36: 9023.Theelen W, Peulen H, Lalezari F, de Vries J, De Langen J, Aerts J. Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: the PEMBRO-RT study. J Clin Oncol 2018;36: 9023.Anti-PD 1 brain collaboration ю radiotherapy: the ABC–X Study. Available at: https://clinicaltrials.gov/ct2/show/NCT03340129Anti-PD 1 brain collaboration ю radiotherapy: the ABC–X Study. Available at: https://clinicaltrials.gov/ct2/show/NCT03340129Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, Thelen M, Schill C, Merki R, Schmid T, Koeberle D, Zippelius A, Baues C, Mauch C, Tigges C, Kreuter A, Borggrefe J, von Bergwelt-Baildon M, Schlaak M. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Cancer Immunol Res 2016; 4 (9): 744–754. https://doi.org/10.1158/2326–6066.CIR-15–0156.Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, Thelen M, Schill C, Merki R, Schmid T, Koeberle D, Zippelius A, Baues C, Mauch C, Tigges C, Kreuter A, Borggrefe J, von Bergwelt-Baildon M, Schlaak M. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Cancer Immunol Res 2016; 4 (9): 744–754. https://doi.org/10.1158/2326–6066.CIR-15–0156.

The authors declare that there are no conflicts of interest present.